Can Breast Cancer Molecular Subtype Help to Select Patients for Preoperative MR Imaging?

被引:59
作者
Grimm, Lars J. [1 ]
Johnson, Karen S. [1 ]
Marcom, P. Kelly [2 ]
Baker, Jay A. [1 ]
Soo, Mary S. [1 ]
机构
[1] Duke Univ, Dept Radiol, Med Ctr, Durham, NC 27710 USA
[2] Duke Univ, Dept Radiol, Dept Med Oncol, Durham, NC 27710 USA
关键词
PROGESTERONE-RECEPTOR; PATHOLOGICAL RESPONSE; ESTROGEN-RECEPTOR; NODE-METASTASIS; CLASSIFICATION; CHEMOTHERAPY; ACCURACY; PATTERNS; WOMEN;
D O I
10.1148/radiol.14140594
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess whether breast cancer molecular subtype classified by surrogate markers can be used to predict the extent of clinically relevant disease with preoperative breast magnetic resonance (MR) imaging. Materials and Methods: In this HIPAA-compliant, institutional review boardapproved study, informed consent was waived. Preoperative breast MR imaging reports from 441 patients were reviewed for multicentric and/or multifocal disease, lymph node involvement, skin and/or nipple invasion, chest wall and/or pectoralis muscle invasion, or contralateral disease. Pathologic reports were reviewed to confirm the MR imaging findings and for hormone receptors (estrogen and progesterone subtypes), human epidermal growth factor receptor type 2 (HER2 subtype), tumor size, and tumor grade. Surrogates were used to categorize tumors by molecular subtype: hormone receptor positive and HER2 negative (luminal A subtype); hormone receptor positive and HER2 positive (luminal B subtype); hormone receptor negative and HER2 positive (HER2 subtype); hormone receptor negative and HER2 negative (basal subtype). All patients included in the study had a histologic correlation with MR imaging findings or they were excluded. x(2) analysis was used to compare differences between subtypes, with multivariate logistic regression analysis used to assess for variable independence. Results: Identified were 289 (65.5%) luminal A, 45 (10.2%) luminal B, 26 (5.9%) HER2, and 81 (18.4%) basal subtypes. Among subtypes, significant differences were found in the frequency of multicentric and/or multifocal disease (luminal A, 27.3% [79 of 289]; luminal B, 53.3% [24 of 45]; HER2, 65.4% [17 of 26]; basal, 27.2% [22 of 81]; P <.001) and lymph node involvement (luminal A, 17.3% [50 of 289]; luminal B, 35.6% [26 of 45]; HER2, 34.6% [nine of 26]; basal 24.7% [20 of 81]; P =.014). Multivariate analysis showed that molecular subtype was independently predictive of multifocal and/or multicentric disease. Conclusion: Preoperative breast MR imaging is significantly more likely to help detect multifocal and/or multicentric disease and lymph node involvement in luminal B and HER2 molecular subtype breast cancers. Molecular subtype may help to select patients for preoperative breast MR imaging.
引用
收藏
页码:352 / 358
页数:7
相关论文
共 35 条
[1]   Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma [J].
Andea, AA ;
Wallis, T ;
Newman, LA ;
Bouwman, D ;
Dey, J ;
Visscher, DW .
CANCER, 2002, 94 (05) :1383-1390
[2]   Luminal-B breast cancer and novel therapeutic targets [J].
Ben Tran ;
Bedard, Philippe L. .
BREAST CANCER RESEARCH, 2011, 13 (06)
[3]   Magnetic Resonance Imaging Screening of the Contralateral Breast in Women With Newly Diagnosed Breast Cancer: Systematic Review and Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management [J].
Brennan, Meagan Elizabeth ;
Houssami, Nehmat ;
Lord, Sarah ;
Macaskill, Petra ;
Irwig, Les ;
Dixon, J. Michael ;
Warren, Ruth M. L. ;
Ciatto, Stefano .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5640-5649
[4]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[5]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[6]   Accuracy of Breast Magnetic Resonance Imaging in Predicting Pathologic Response in Patients Treated With Neoadjuvant Chemotherapy [J].
De Los Santos, Jennifer ;
Bernreuter, Wanda ;
Keene, Kimberly ;
Krontiras, Helen ;
Carpenter, John ;
Bland, Kirby ;
Cantor, Alan ;
Forero, Andres .
CLINICAL BREAST CANCER, 2011, 11 (05) :312-319
[7]   Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status [J].
Fernandez-Morales, Luis A. ;
Segui, Miquel A. ;
Andreu, Xavier ;
Dalmau, Elsa ;
Saez, Amparo ;
Pericay, Carles ;
Santos, Cristina ;
Montesinos, Jesus ;
Gallardo, Enrique ;
Arcusa, Angels ;
Saigi, Eugeni .
CLINICAL BREAST CANCER, 2007, 7 (07) :559-564
[8]   Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis A Randomized Clinical Trial [J].
Giuliano, Armando E. ;
Hunt, Kelly K. ;
Ballman, Karla V. ;
Beitsch, Peter D. ;
Whitworth, Pat W. ;
Blumencranz, Peter W. ;
Leitch, A. Marilyn ;
Saha, Sukamal ;
McCall, Linda M. ;
Morrow, Monica .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (06) :569-575
[9]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223
[10]   Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy [J].
Goldstein, Neal S. ;
Decker, David ;
Severson, Dawn ;
Schell, Scoff ;
Vicini, Frank ;
Margolis, Jeffrey ;
Dekhne, Nayana S. .
CANCER, 2007, 110 (08) :1687-1696